HIGH-DOSE-RATE AND LOW-DOSE-RATE BRACHYTHERAPY AS MONOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Voprosy onkologii, v. 65, n. 3, p. 434–440, 1 Mar.2019.